July 27 (Reuters) - Almirall SA ALM.MC :
* Says enters into a license agreement with Sun Pharma Industries SUN.NS for tildrakizumab in Europe for psoriasis
* Says to pay Sun Pharma an initial upfront payment of $50 million
* Says Sun Pharma will be eligible to get milestone payments, sales milestone payments and royalties on net sales
* Says phase-3 studies of tildrakizumab have recently been completed
Source text for Eikon: ID:nCNM4C7tkf , company coverage: ALM.MC
(Gdynia Newsroom)